Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (referred to as "Fudan-Zhangjiang" or "the company") recently released its 2025 performance forecast, revealing startling figures. While operating revenue saw only a slight decline of 3.33%, net profit attributable to shareholders plummeted from a profit of 39.7339 million yuan the previous year to a loss of 157 million yuan, a dramatic drop of 496.23% year-on-year, indicating a near-collapse in profitability.

This performance not only highlights the company's heavy reliance on a single core product but also exposes multiple imbalances in its response to policy changes, research and development investments, and cost control. The following is an in-depth analysis of the major risks and challenges currently facing the company:

1. **Core Product Fails National Procurement, Severely Impacting Profitability** The report indicates that the company's core product, Libao® (doxorubicin hydrochloride liposome injection), failed to win selection in the national centralized drug procurement program. As a result, the company reduced the product's market price starting May 2025, leading to an approximate decrease of 100 million yuan in its profit contribution compared to the previous year. This event underscores the risks associated with the company's highly concentrated product portfolio and its weak resilience to policy changes. Against the backdrop of normalized centralized procurement, the failure of a single blockbuster product can deliver a devastating blow to the company's overall performance.

2. **Surging R&D Investment Yields No Short-Term Returns** In 2025, the company's R&D expenditure reached 358 million yuan, an increase of approximately 44 million yuan year-on-year, with its proportion of operating revenue rising significantly. Although the company is actively expanding in the ADC (antibody-drug conjugate) field, with several projects advancing to late-stage clinical trials—such as FDA018 (anti-Trop2 ADC) completing Phase III enrollment and FDA022 (anti-Her2 ADC) entering the EOP2 stage—demonstrating some R&D potential, it is crucial to note that these projects remain in clinical trials. These initiatives are unable to generate revenue or profit in the short term and instead exacerbate the current financial strain. For a company already facing losses, sustained high-intensity R&D investment is creating dual pressure on both cash flow and profitability.

3. **Rising Costs Erode Already Thin Profit Margins** During the reporting period, the company's sales expenses surged by 41.53% year-on-year, financial expenses increased sharply by 76.56%, and administrative expenses grew slightly by 4.39%. Against the backdrop of declining revenue, the comprehensive rise in costs further compressed profit margins, revealing significant shortcomings in the company's operational efficiency and cost control. The sharp increase in sales expenses is likely related to intensified market promotion efforts following the procurement setback. However, if this "spending-for-volume" strategy fails to generate corresponding sales growth, it may prove unsustainable.

4. **Deteriorating Cash Flow and Shrinking Asset Base** The company's net cash flow from operating activities decreased substantially. Total assets at the period-end decreased by 7.57% compared to the start of the year, and equity attributable to shareholders decreased by 8.17%. This series of data indicates that the company is not only experiencing declining profitability but has also begun consuming its own asset reserves to sustain operations. If profitability does not improve, the company could face greater liquidity pressures in the future.

**Conclusion** Fudan-Zhangjiang's 2025 performance can be seen as a concentrated eruption of "structural risks." The interplay of multiple issues—the core product's procurement failure, high R&D investment without short-term returns, uncontrolled costs, and deteriorating cash flow—reflects significant weaknesses in the company's strategic planning, risk prevention, and financial management. For investors, the focus should now be on whether the company can stabilize its core business in the short term, optimize its cost structure, and expedite the commercialization of its pipeline products. Otherwise, the "precipitous decline" of 2025 might only be the beginning.